Herceptin® Receives New FDA Approval
The FDA approved the use of Herceptin® (trastuzumab) as part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel (chemotherapy) for the adjuvant treatment of HER2-postive, node-positive breast cancer on November 16. To read details regarding this action, please click here.